|Last Price$4.28||Day Change (%)-0.70%|
|Open Price$4.31||Day Change ($)-0.03|
|Day Range4.22–4.36||52-Week Range3.96–13.26|
As of Fri 08/29/2014 04:00 PM EST | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.